Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(1998): Corazza M+, Contact Dermatitis 38(6), 356
(1997): Balato N+, Am J Contact Dermat 8(1), 24
(1992): Aramoto Y+, JDermatol19(6), 375
Erythroderma
(1991): Fernandez de+, Contact Dermatitis 25(1), 68
Kaposi’s sarcoma
(2004): Monti M+, J Eur Acad Dermatol Venereol 18(2), 191
Perioral dermatitis
(2001): Chow ET, Australas J Dermatol 42(1), 62
Pruritus
(2005): Hardy D, Can J Anaesth 52(2), 186 (with bupivacaine &
epinephrine)
(2002): Mignogna MD+, JOralPatholMed31(6), 339
Rash (sic)
(2004): Kuga A+, Rinsho Shinkeigaku 44(10), 691
(2001): Macchia PE+, J Endocrinol Invest 24(3), 152
Stevens–Johnson syndrome
(2002): Samimi SS+, Pediatr Dermatol 19(1), 52
Thinning
Urticaria
(2001): Borja JM+, Allergy 56(8), 791
(2001): Pollack B+, Br J Dermatol 144, 1228
(1996): Pizzuti P+, Rev Rhum Engl Ed 63(3), 223
(1990): Sieck JO+, Br J Clin Pract 44(12), 723
Hair
Hair – hypertrichosis
Eyes
Cataract
(2003): Nakamura T+, Jpn J Ophthalmol 47(3), 254 (with
cyclosporine)
(1999): Marsh P+, Ophthalmology 106(4), 811
(1992): Yokota S+, Ryumachi 32(3), 215
Conjunctival ulceration
(1999): Zamir E+, Ophthalmic Surg Lasers 30(7), 565
Glaucoma
(1995): Katsushima H, Nippon Ganka Gakkai Zasshi 99(2), 238
(1992): Yokota S+, Ryumachi 32(3), 215
Ocular pain
Ocular pressure
(1999): Marsh P+, Ophthalmology 106(4), 811
Ophthalmitis
(2003): Mazur-Chlodek L+, Klin Oczna 105(3-4), 194
Periorbital urticaria
(1992): John GR+, Am J Ophthalmol 113(5), 588
Visual disturbances
(1991): Bettinelli A+, Child Nephrol Urol 11(1), 41
Other
Abdominal pain
(1994): Chassard D+, Presse Med 23(11), 515
Adverse effects
(2005): Chibane S+, Rev Med Interne 26(1), 20
(1992): Pozzi C+, Nephron 60(2), 235
Anaphylactoid reactions/Anaphylaxis
(2004): Saito R+, Int J Urol 11(3), 171
(2002): Burgdorff T+, Ann Allergy Asthma Immunol 89(4), 425
(2000): Young MF+, J Neurol Neurosurg Psychiatry 68(2), 255
(1999): Beynel P+, Rev Mal Respir 16(4), 529
(1999): Schonwald S, Am J Emerg Med 17(6), 583
(1997): Mace S+, J Rheumatol 24(6), 1191
(1997): van den Berg JS+, J Neurol Neurosurg Psychiatry
63(6), 813
(1996): Moreno-Ancillo A+, J Allergy Clin Immunol 97(5), 1169
(1993): Hopper JM+, J Bone Joint Br 75(3), 505 (with
bupivacaine)
(1993): Watanabe I+, Masui 42(1), 112
(1991): Peces R+, Nephron 59(3), 497
METHYLTESTOSTERONE 361
(1990): Laine-Cessac P+, Therapie 45(6), 505
Hepatotoxicity
(2006): Topal F+, Ann Pharmacother 40(10), 1868
Hypersensitivity
(2006): Sirvent AE+, Nefrologia 26(1), 128
(2006): Venturini M+, J Investig Allergol Clin Immunol 16(1), 51
(1996): Lopez-Serrano MC+, J Investig Allergol Clin Immunol
6(5), 324
Infections
(2004): Kulig G+, Przegl Lek 61(8), 855
(2004): Offidani M+, Leuk Lymphoma 45(8), 1617
(2004): Tanaka Y, Nippon Rinsho 62(10), 1867
(1994): Sayer HG+, Blood 84(4), 1328
(1992): Baethge BA+, Ann Pharmacother 26(3), 316
Injection-site lipoatrophy
(2000): Anderson B+, Arch Intern Med 151, 153
Lymphoproliferative disease
(2002): Theate I+, Eur J Haematol 69(4), 248 (with
methotrexate)
Myalgia/Myositis/Myopathy/Myotoxicity
(2006): Lee HJ+, Bone Marrow Transplant 38(4), 299
(2005): Qian T+, Spinal Cord 43(4), 199
(2001): Odabas AR+, Nephron 87(1), 95
(2000): Qian T+, Med Hypotheses 55(5), 452
Neurotoxicity
(2004): Fodale V+, Br J Anaesth 92(2), 289 (with cisatracurium)
Tendinopathy/Tendon rupture
(2005): Chiou YM+, Lupus 14(4), 321
METHYLTESTOSTERONE
Trade names: Android (Valeant); Androral; B; Enarmon;
Estratest (Solvay); Metandren; Teston; Testotonic ‘B’; Testovis;
Testred (Valeant); Virilon; Viromone
Indications: Hypogonadism, impotence, metastatic breast
cancer
Category: Androgen
Half-life: 2.5–3.5 hours
Clinically important, potentially hazardous interactions
with: anticoagulants, cyclosporine, warfarin
Reactions
Skin
Acanthosis nigricans
(1987): Shuttleworth D+, Clin Exp Dermatol 12, 288
Acne (>10%)
(1992): Fryand O+, Acta Derm Venereol 72, 148
(1990): Fuchs E+, JAmAcadDermatol23, 125
(1989): Fryand O+, Tidsskr Nor Laegeforen (Norwegian)
109, 239
(1989): Hartmann AA+, Monatsschr Kinderheilkd (German)
137, 466
(1989): Heydenreich G, Arch Dermatol 125, 571 (fulminans)
(1989): Scott MJ+, Cutis 44, 30
(1989): von Muhlendahl KE+, Dtsch Med Wochenschr (German)
114, 712
(1988): Traupe H+, Arch Dermatol 124, 414 (fulminans)
(1987): Kiraly CL+, Am J Dermatopathol 9, 515
(1984): Lamb DR, Am J Sports Med 12, 31
Dermatitis
(1989): Holdiness MR, Contact Dermatitis 20, 3 (from patch)
Edema (>10%)
Exanthems
Furunculosis
(1989): Scott MJ+, Cutis 44, 30